Comparative analysis reveals potential of circulating free DNA in diagnosing pancreatic cancer, suggesting improved monitoring.
Liquid biopsies enable non-invasive tumor material sampling in patients with pancreatic adenocarcinoma (PDAC). Genetic information, especially alterations in circulating free DNA (cfDNA) levels, might help to predict poorer tumor differentiation, disease progression and might be used as treatment efficacy evaluator. However, the data on this topic is insufficient.
No takes yet. Share an insight, caveat, or question.
Riauka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: